Takeda Pharmaceutical Company Limited TAK
21.06 USD +0.31 (+1.49%)
At closeNov 4, 2026, 7:53 PM EST
21.92 +0.86 +4.10%
After hours · Nov 4, 7:53 PM ET
20.65 Day range 21.08
13.50 52-week range 21.22
- YTD
- +35.09%
- 1 year
- +55.31%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 22.94 +8.9% upside
Now 21.06
- Target (low)
- 20.92
- Target (mean)
- 22.94
- Target (high)
- 25.90
Ratings (0m) 3 3 buy · 0 hold · 0 sell
- Strong buy0
- Buy3
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 3
- 1 month ago 3
- 2 months ago 3
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 1.24T | +3.7% | 0 |
| Next quarter | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 1.14T | +4.1% | 0 |
| Current year | 148.67 | 51.16 – 246.19 | 61.00 | +143.7% | 4.71T | +695.5% | 2 |
| Next year | 198.63 | 138.53 – 258.73 | 148.67 | +33.6% | 4.81T | +2.3% | 2 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 16, 2023 | TD Cowen | Maintained | Outperform | Outperform |
| Apr 4, 2023 | TD Cowen | Maintained | — | Outperform |
| Mar 16, 2023 | B of A Securities | Upgrade | Neutral | Buy |
| Jul 19, 2022 | Cowen & Co. | Upgrade | Market Perform | Outperform |
| Oct 7, 2021 | Morgan Stanley | Downgrade | Overweight | Equal-Weight |
| Mar 11, 2020 | JP Morgan | Maintained | — | Overweight |
| Nov 1, 2019 | Cowen & Co. | Initiated | — | Market Perform |
| Sep 24, 2019 | Jefferies | Initiated | — | Buy |